FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Saturday

 

Health Canada Approves PLEGRIDY™ (peginterferon Beta-1a) For Adults With Relapsing Remitting Multiple Sclerosis






























PLEGRIDY™ is the first and only pegylated interferon administered once every two weeks for the treatment of MS

Today, Biogen Canada Inc. announces the Health Canada approval of PLEGRIDY TM (peginterferon beta-1a), which has been approved for the treatment of adults with relapsing remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and to slow the progression of disability. 1 PLEGRIDY™ offers a unique combination of demonstrated efficacy, a favourable safety profile consistent with the established interferon class, and an every two week dosing schedule. 1

"PLEGRIDY is the first interferon dosed once every two weeks, which reduces the frequency of relapses and slows the progression of disability in people living with RRMS," said Dr. Marcelo Kremenchutzky, Director of the Multiple Sclerosis Clinic in London, Ontario. "PLEGRIDY provides the safety profile we have come to expect from an interferon, with demonstrated efficacy and the added convenience of a reduced dosing schedule."

Multiple Sclerosis (MS) is a chronic, often disabling disease that attacks the central nervous system (CNS), which is made up of the brain, spinal cord and optic nerves. Symptoms result, at least in part, from when a person's immune system attacks the protective covering, or myelin, of the brain and spinal cord and interferes with the transmission of nerve signals between the brain, spinal cord and other parts of the body. 2

PLEGRIDY™ is a new molecular entity, resulting from the application of pegylation technology. Pegylation prolongs circulation time by: increasing molecular size resulting in a longer half-life, stabilizes the molecule by improving chemical stability and solubility for a longer shelf-life and shields from degradation and decreased immunogenicity. 3 This allows patients to receive an interferon treatment with less frequent dosing. Beta interferons, like PLEGRIDY™, are a commonly-used class of RRMS treatments which are thought to resemble the body's natural interferon that works with the immune system and helps regulate the body's immune response; however, the exact mechanism is not known. 1 It is thought that beta interferon can reduce (and might prevent) inflammation which can damage nerve fibres in MS. 4

"We are pleased that Health Canada has been responsive in listing another disease-modifying therapy for those with multiple sclerosis," says Sylvia Leonard, National Vice President, Programs and Services, MS Society of Canada.

 "This responsiveness means that Canadians with MS have a more diverse range of treatment options available to them to meet their needs and lifestyles.

Individuals with MS who are interested in exploring treatment options are encouraged to consult with their healthcare team to find the course that is most appropriate for them."

Story Source: The above story is based on materials provided by THESTREET
Note: Materials may be edited for content and length

Labels:



Go to Newer News Go to Older News